S&P/ASX 200 Index (ASX: XJO) shares are 0.8% higher at 9,099.8 points on Tuesday.
Christopher Watt from Bell Potter has named three ASX 200 shares to buy, hold, and sell this week (courtesy The Bull).
Let's learn from his insights.
Image source: Getty Images
WiseTech Global Ltd (ASX: WTC)
The Wisetech Global share price is $46.41, up 2.5% today.
Watt has a buy rating on this ASX 200 tech share.
Watt said WiseTech delivered solid revenue and earnings in FY26, with strong cash flow and a better than expected dividend.
However, the market is concerned that FY27 earnings will be stronger in the second half, leaving less room for error in the first.
This concern is reflected in WiseTech Global's weakened share price, down 34% in 2026.
However, Watt says this has opened up a good entry point for WiseTech shares.
He explained:
The company is now trading on far more appealing multiples in full year 2027, which are well below historical levels for a business of this quality.
Investors appear to have noticed the opportunity, with WiseTech shares jumping 33% in the past month alone.
CSL Ltd (ASX: CSL)
The CSL share price is $200.52, down 0.1% today.
Watt has a hold rating on this ASX 200 healthcare share following its extraordinary rebound in FY27 so far.
CSL shares fell to a nine-year low of $90 in May.
Over the past six months, the stock has doubled in value alongside a broader healthcare sector recovery.
Watt noted recovering plasma sales and better-than-expected FY27 guidance from the company.
He reckons the worst of the biotech's earnings downgrades are behind it, and CSL shares are worth holding for now.
He said:
… revenue is expected to be flat in full year 2027, the Vifor division is shrinking and the shares already trade at a premium to global peers.
After a strong rebound from its share price lows, we would continue holding existing positions.
Wesfarmers Ltd (ASX: WES)
The Wesfarmers share price is $80.60, up 0.5% today.
Watt has a sell recommendation on this ASX 200 consumer discretionary share.
At the recent AGM, Wesfarmers spoke of moderating sales growth at Bunnings amid Australia's cost-of-living crisis.
Watt explained the significance, commenting:
Bunnings is the group's main earnings driver, which in our view, puts market forecasts at risk, which already look too high.
Watt reckons Wesfarmers shares are already trading at a premium.
In light of all this, Watt suggests investors consider taking profits or reducing exposure.
